Results 1 to 10 of about 453,251 (315)

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis. [PDF]

Hepatology, 2023
Background and Aims: Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with portal hypertension. JAK2 inhibitors, such as pacritinib, are already in advanced clinical development for other indications and might also be
Torres S, Ortiz C, Bachtler N, Gu W, Grünewald LD, Kraus N, Schierwagen R, Hieber C, Meier C, Tyc O, Joseph Brol M, Uschner FE, Nijmeijer B, Welsch C, Berres ML, Garcia-Ruiz C, Fernandez-Checa JC, Trautwein C, Vogl TJ, Zeuzem S, Trebicka J, Klein S.   +21 more
europepmc   +3 more sources

Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor

Journal of Experimental Pharmacology, 2016
Jack W Singer,1 Suliman Al-Fayoumi,1 Haiching Ma,2 Rami S Komrokji,3 Ruben Mesa,4 Srdan Verstovsek5 1Translational Medicine, CTI BioPharma Corp., Seattle, WA, 2Department of Research and Development, Reaction Biology, Malvern, PA, 3Department of ...
Singer J, Al-Fayoumi S, Ma H, Komrokji R, Mesa R, Verstovsek S   +5 more
doaj   +6 more sources

Selective Janus Kinase 2 (JAK2) Pseudokinase Ligands with a Diaminotriazole Core. [PDF]

J Med Chem, 2020
Janus kinases (JAKs) are non-receptor tyrosine kinases that are essential components of the JAK-STAT signaling pathway. Associated aberrant signaling is responsible for many forms of cancer and disorders of the immune system.
Liosi ME, Krimmer SG, Newton AS, Dawson TK, Puleo DE, Cutrona KJ, Suzuki Y, Schlessinger J, Jorgensen WL.   +8 more
europepmc   +5 more sources

Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations [PDF]

Haematologica, 2014
Somatic insertions/deletions in the calreticulin gene have recently been discovered to be causative alterations in myeloproliferative neoplasms. A combination of qualitative and quantitative allele-specific polymerase chain reaction, fragment-sizing ...
Hajnalka Andrikovics, Tunde Krahling, Katalin Balassa, Gabriella Halm, Andras Bors, Magdalena Koszarska, Arpad Batai, Janos Dolgos, Judit Csomor, Miklos Egyed, Andrea Sipos, Peter Remenyi, Attila Tordai, Tamas Masszi   +13 more
doaj   +3 more sources

Functional and Structural Characterization of Clinical-Stage Janus Kinase 2 Inhibitors Identifies Determinants for Drug Selectivity. [PDF]

J Med Chem
Janus kinase 2 (JAK2) plays a critical role in orchestrating hematopoiesis, and its deregulation leads to various blood disorders, most importantly myeloproliferative neoplasms (MPNs).
Miao Y, Virtanen A, Zmajkovic J, Hilpert M, Skoda RC, Silvennoinen O, Haikarainen T.   +6 more
europepmc   +2 more sources

The prolactin receptor scaffolds Janus kinase 2 via co-structure formation with phosphoinositide-4,5-bisphosphate [PDF]

eLife, 2023
Class 1 cytokine receptors transmit signals through the membrane by a single transmembrane helix to an intrinsically disordered cytoplasmic domain that lacks kinase activity. While specific binding to phosphoinositides has been reported for the prolactin
Raul Araya-Secchi, Katrine Bugge, Pernille Seiffert, Amalie Petry, Gitte W Haxholm, Kresten Lindorff-Larsen, Stine Falsig Pedersen, Lise Arleth, Birthe B Kragelund   +8 more
doaj   +2 more sources

-escin mitigates neuroinflammation and apoptosis caused by ischemic stroke through the inhibition of the interleukin-6/Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway [PDF]

Journal of International Medical Research
Objective This study aimed to investigate the protective effects of β-escin against neuroinflammatory injury and its influence on the interleukin-6/Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway in a rat model of ...
Duan Yanqin, Liu Shenglan, Zhang Yu, Deng Yu, Du Qing, Zeng Hongliang, Tan Dianbo, Liu Chunhai, Yin yong, Liu Dongliang   +9 more
doaj   +2 more sources

Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations. [PDF]

J Allergy Clin Immunol, 2019
Background Janus kinases (JAKs; JAK1 to JAK3 and tyrosine kinase 2) mediate cytokine signals in the regulation of hematopoiesis and immunity. JAK2 clinical mutations cause myeloproliferative neoplasms and leukemia, and the mutations strongly concentrate ...
Hammarén HM, Virtanen AT, Abraham BG, Peussa H, Hubbard SR, Silvennoinen O.   +5 more
europepmc   +2 more sources

Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders

Pharmacological Research, 2022
The Janus kinase (JAK) family of nonreceptor protein-tyrosine kinases consists of JAK1, JAK2, JAK3, and TYK2 (Tyrosine Kinase 2). Each of these proteins contains a JAK homology pseudokinase (JH2) domain that interacts with and regulates the activity of ...
Robert Roskoski, Jr.
doaj   +2 more sources

Serum amyloid A and Janus kinase 2 in a mouse model of diabetic kidney disease. [PDF]

PLoS One, 2019
Background Serum amyloid A (SAA), a potent inflammatory mediator, and Janus kinase 2 (JAK2), an intracellular signaling kinase, are increased by diabetes. The aims were to elucidate: 1) a JAK2-mediated pathway for increased SAA in the kidneys of diabetic
Dieter BP, Meek RL, Anderberg RJ, Cooney SK, Bergin JL, Zhang H, Nair V, Kretzler M, Brosius FC, Tuttle KR.   +9 more
europepmc   +2 more sources